Dr. Zach Cost, an anesthesia resident at Massachusetts General Hospital, and Dr. Pavan Bendapudi, assistant professor at Harvard Medical School, delve into tranexamic acid (TXA) and its relationship with thromboembolic risk. They dissect the clash between TXA's hemostatic benefits and potential dangers, referencing pivotal studies like CRASH-2. Their conversation also covers differentiating TXA from Amicar regarding efficacy and risks, while exploring its effectiveness in surgery and the complexities surrounding antifibrinolytic therapy.
